Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1973 1
1977 2
1979 2
1980 1
1981 4
1982 5
1983 1
1985 2
1986 2
1987 1
1988 1
1989 3
1990 9
1991 15
1992 11
1993 16
1994 15
1995 12
1996 6
1997 11
1998 5
1999 8
2000 7
2001 12
2002 12
2003 6
2004 11
2005 13
2006 12
2007 15
2008 24
2009 24
2010 30
2011 23
2012 22
2013 28
2014 31
2015 26
2016 26
2017 40
2018 32
2019 16
2020 27
2021 21
2022 29
2023 16
2024 31
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

604 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. White WB, et al. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12. N Engl J Med. 2018. PMID: 29527974 Free article. Clinical Trial.
We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopurinol, a purine base analogue xanthine oxidase inhibitor, in patients with gout and cardiovascular disease. ...CONCLUSIONS: In patients …
We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopu …
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Free article. Clinical Trial.
BACKGROUND: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safety of f …
BACKGROUND: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the ca …
Effects of Allopurinol on the Progression of Chronic Kidney Disease.
Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, Clarke P, Dalbeth N, Day RO, de Zoysa JR, Douglas B, Faull R, Harris DC, Hawley CM, Jones GRD, Kanellis J, Palmer SC, Perkovic V, Rangan GK, Reidlinger D, Robison L, Walker RJ, Walters G, Johnson DW; CKD-FIX Study Investigators. Badve SV, et al. N Engl J Med. 2020 Jun 25;382(26):2504-2513. doi: 10.1056/NEJMoa1915833. N Engl J Med. 2020. PMID: 32579811 Clinical Trial.
Whether urate-lowering treatment with allopurinol can attenuate the decline of the estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease who are at risk for progression is not known. ...Serious adverse events were reported in 84 of 182 patient …
Whether urate-lowering treatment with allopurinol can attenuate the decline of the estimated glomerular filtration rate (eGFR) in pat …
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Becker MA, et al. N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373. N Engl J Med. 2005. PMID: 16339094 Free article. Clinical Trial.
Although the incidence of gout flares diminished with continued treatment, the overall incidence during weeks 9 through 52 was similar in all groups: 64 percent of patients receiving 80 mg of febuxostat, 70 percent of those receiving 120 mg of febuxostat, and 64 percent of those …
Although the incidence of gout flares diminished with continued treatment, the overall incidence during weeks 9 through 52 was similar in al …
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Schumacher HR Jr, et al. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209. Arthritis Rheum. 2008. PMID: 18975369 Clinical Trial.
OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function. ...The primary reasons for withdrawal were similar across groups e …
OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects wit …
Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis.
van der Pol KH, Wever KE, Verbakel M, Visseren FLJ, Cornel JH, Rongen GA. van der Pol KH, et al. PLoS One. 2021 Dec 2;16(12):e0260844. doi: 10.1371/journal.pone.0260844. eCollection 2021. PLoS One. 2021. PMID: 34855873 Free PMC article.
AIMS: To compare the effectiveness of allopurinol with no treatment or placebo for the prevention of cardiovascular events in hyperuricemic patients. ...Cardiovascular benefit was only observed when allopurinol therapy was prolonged for more than 6 months and when a …
AIMS: To compare the effectiveness of allopurinol with no treatment or placebo for the prevention of cardiovascular events in hyperur …
Efficacy of Allopurinol in Improving Endothelial Dysfunction: A Systematic Review and Meta-Analysis.
Qazi SU, Qamar U, Maqsood MT, Gul R, Ansari SA, Imtiaz Z, Noor A, Suheb MZK, Zaheer Z, Andleeb A, Naseem M, Akram MS, Ali M, Barmanwalla A, Tareen R, Zaheer I. Qazi SU, et al. High Blood Press Cardiovasc Prev. 2023 Nov;30(6):539-550. doi: 10.1007/s40292-023-00615-z. Epub 2023 Dec 9. High Blood Press Cardiovasc Prev. 2023. PMID: 38070035
However, there was no significant difference between allopurinol and control for endothelial-independent vasodilation measured by forearm blood flow (WMD = 0.10%, 95% CI [- 0.89, 0.69], p = 0.80). Subgroup analysis indicated that the effect of allopurinol on FMD was …
However, there was no significant difference between allopurinol and control for endothelial-independent vasodilation measured by for …
Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial.
Helget LN, Davis-Karim A, O'Dell JR, Mikuls TR, Newcomb JA, Androsenko M, Brophy MT, England BR, Ferguson R, Pillinger MH, Neogi T, Wu H, Palevsky PM. Helget LN, et al. Am J Kidney Dis. 2024 Nov;84(5):538-545. doi: 10.1053/j.ajkd.2024.04.017. Epub 2024 Jun 19. Am J Kidney Dis. 2024. PMID: 38906504 Clinical Trial.
CONCLUSIONS: Allopurinol and febuxostat are similarly efficacious and well-tolerated in the treatment of gout in people with CKD when used in a treat-to-target regimen with lower incidence of gout flares in participants randomized to allopurinol. ...A significant pr …
CONCLUSIONS: Allopurinol and febuxostat are similarly efficacious and well-tolerated in the treatment of gout in people with CKD when …
Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial.
Stamp L, Horne A, Mihov B, Drake J, Haslett J, Chapman PT, Frampton C, Dalbeth N. Stamp L, et al. Ann Rheum Dis. 2023 Dec;82(12):1626-1634. doi: 10.1136/ard-2023-224731. Epub 2023 Aug 31. Ann Rheum Dis. 2023. PMID: 37652661 Clinical Trial.
OBJECTIVES: To determine whether placebo is non-inferior to low-dose colchicine for reducing gout flares during the first 6 months of allopurinol using the 'start-low go-slow' dose approach. METHODS: A 12-month double-blind, placebo-controlled non-inferiority trial was und …
OBJECTIVES: To determine whether placebo is non-inferior to low-dose colchicine for reducing gout flares during the first 6 months of all …
Effects of allopurinol on renal function in patients with diabetes: a systematic review and meta-analysis.
Luo Q, Cai Y, Zhao Q, Tian L, Liu Y, Liu WJ. Luo Q, et al. Ren Fail. 2022 Dec;44(1):806-814. doi: 10.1080/0886022X.2022.2068443. Ren Fail. 2022. PMID: 35856157 Free PMC article.
Therefore, this meta-analysis [PROSPERO CRD42021274465] intended to evaluate the efficacy and safety of allopurinol in patients with diabetes mellitus. METHODS: We thoroughly searched five electronic resource databases for randomized controlled trials (RCTs) that compared …
Therefore, this meta-analysis [PROSPERO CRD42021274465] intended to evaluate the efficacy and safety of allopurinol in patients with …
604 results